Der Onkologe

, Volume 11, Issue 9, pp 933–941 | Cite as

Behandlung mittlerer Stadien beim Hodgkin-Lymphom



In der DHSG werden die meisten Patienten in klinischem Stadium I und II mit spezifischen Risikofaktoren der Gruppe der mittleren (intermediären) Stadien zugeordnet. Die Standardtherapie besteht in der Regel aus einer kombinierten Radiochemotherapie mit 4 Zyklen ABVD und 30 Gy Involved-Field-Strahlentherapie. Aktuell wird in klinischen Studien geprüft, ob durch weitere Intensivierung der Chemotherapie das Outcome bezüglich der Rezidivrate und des Gesamtüberleben verbessert werden kann: Für Patienten unter 60 Jahre wird das BEACOPP-eskaliert-Schema in die Behandlung der mittleren Stadien eingeführt (HD14-Studie der DHSG). Für Patienten über 60 wird das sog. BACOPP-Schema im Rahmen einer neuen Phase-II-Studie evaluiert.


Hodgkin-Lymphom Intermediäre Stadien Risikofaktoren Chemotherapie Involved-Field-Strahlentherapie 

Treatment of early unfavorable stages


In the GHSH, most patients who present clinical stage I or II with certain risk factors are allocated to the early-stage unfavorable (intermediate) group. The standard therapy usually consists of combined modality treatment including four cycles of ABVD followed by 30 Gy of involved-field radiotherapy. Currently, clinical trials investigate whether a further intensification of chemotherapy can improve outcome in terms of both relapses and overall survival. For patients below the age of 60 years, the BEACOPP escalated regimen is being introduced in the treatment of early-unfavorable stages (HD14 trial of the GHSG). For patients above the age of 60, the BACOPP regimen is being evaluated in a new phase II study.


Hodgkin’s lymphoma Early-stage unfavorable Risk factors Chemotherapy Involved-field radiotherapy 


  1. 1.
    Ballova V, Rueffer JU, Haverkamp H et al. (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (HD9elderly). Ann Oncol 16:124–131Google Scholar
  2. 2.
    Bonadonna G, Zucali R, Monfardini S et al. (1975) Combination chemotherapy of Hodgkin‘s disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 36:252–259Google Scholar
  3. 3.
    Bonadonna G, Bonfante V, Viviani S et al. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22:2835–2841Google Scholar
  4. 4.
    Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484Google Scholar
  5. 5.
    Connors JM, Klimo P, Adams G et al. (1997) Treatment of advanced Hodgkin‘s disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:1638–1645Google Scholar
  6. 6.
    Diehl V, Brillant C, Franklin J et al. (2004) BEACOPP Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12-Trials of the German Hodgkin Study Group (GHSG). Blood 104:307aGoogle Scholar
  7. 7.
    Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395Google Scholar
  8. 8.
    Diehl V, Stein H, Hummel M, Zollinger R, Connors JM (2003) Hodgkin’s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. Hematology (Am Soc Hematol Educ Program) 225–472Google Scholar
  9. 9.
    Dubray B, Henry-Amar M, Meerwaldt JH et al. (1995) Radiation-induced lung damage after thoracic irradiation for Hodgkin’s disease: the role of fractionation. Radiother Oncol 36:211–217Google Scholar
  10. 10.
    Duggan DB, Petroni GR, Johnson JL et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614Google Scholar
  11. 11.
    Engert A, Schiller P, Josting A et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s Lymphoma: Results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608Google Scholar
  12. 12.
    Ferme C, Eghbali H, Habenbeek A et al. (2000) MOPP/ABV (M/A) hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II HD: Comparison of three treatment modalities, preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 96:576aGoogle Scholar
  13. 13.
    Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949–1955Google Scholar
  14. 14.
    Horning SJ, Hoppe RT, Breslin S et al. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637Google Scholar
  15. 15.
    Klimm B, Engert A, Brillant C et al. (2005) Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin’s lymphoma: results of the fourth interim analysis of the HD 11 trial of the GHSG. J Clin Oncol 23:6507aGoogle Scholar
  16. 16.
    Lister T, Crowther D, Sutcliffe S et al. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636Google Scholar
  17. 17.
    Longo DL, Young RC, Wesley M et al. (1986) Twenty years of MOPP chemotherapy for Hodgkin‘s disease. J Clin Oncol 4:1295–1306Google Scholar
  18. 18.
    Ng AK, Bernardo MV, Weller E et al. (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100:1989–1996Google Scholar
  19. 19.
    Noordijk EM, Thomas J, Fermé C et al. (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol 23:6505aGoogle Scholar
  20. 20.
    Raemaekers J, Kluin-Nelemans H, Teodorovic I et al. (2002) The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38:S107–S113Google Scholar
  21. 21.
    Sieber M, Tesch H, Pfistner B et al. (2002) Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin’s lymphoma: final results of the German Hodgkin’s Lymphoma Study Group Trial HD5. J Clin Oncol 20:476–484Google Scholar
  22. 22.
    van Leeuwen FE, Klokman WJ, Stovall M et al. (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95:971–980Google Scholar
  23. 23.
    Zittoun R, Audebert A, Hoerni B et al. (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3:207–214Google Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Klinik I für Innere Medizin/DHSG, Universitätsklinikum Köln
  2. 2.Klinik I für Innere Medizin, DHSG-Studienzentrale, Universitätsklinikum KölnKöln

Personalised recommendations